Value
6.0/10data confidence 33%| Component | Sub-score |
|---|---|
| Analyst target | 6.0 |
RLAY · Why this verdict
Why Relay Therapeutics (RLAY) is rated SELL
Updated
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results.
Show full disclosure ▾Hide full disclosure ▴
About TrendMatrix. TrendMatrix is a publisher of general securities research and market commentary. We publish on a regular schedule. All content is the same for every subscriber in a tier — we do not provide personalized investment advice and we do not take into account any individual subscriber's financial situation, investment objectives, risk tolerance, tax situation, or holdings.
Not investment advice. TrendMatrix is not a registered investment adviser. Our content is for informational and educational purposes only. Consult your own licensed investment adviser, broker, or tax professional before making any investment decision.
Conflicts and positions. The TrendMatrix editorial team frequently holds personal long-term positions in securities discussed. We disclose positions held at the time of publication on each piece. We maintain a trading-window policy: we do not initiate or close positions in the same direction as a TrendMatrix publication within 24 hours before or 72 hours after publication.
No paid promotion. TrendMatrix does not accept payment from any issuer, broker, or third party in exchange for coverage of any security. Our sole compensation is subscription revenue.
No fiduciary duty. No fiduciary, advisory, or agency relationship is created between you and TrendMatrix by reading our content or subscribing to our service.
Performance. Past performance is not indicative of future results. Performance figures reflect the published model only and do not reflect any individual subscriber's actual results.
VerdictSELL
Overall score4.8/10
ConfidenceMEDIUM
MacroNEUTRAL
Thesis pillars
| Pillar | Expectation | Trend |
|---|---|---|
The put-to-call ratio stands at 4.40 with implied volatility near 185%, indicating the options market is pricing in a high probability of significant downside, consistent with binary clinical event risk rather than steady business execution. Options | Put-to-call ratio drops below 2.0 within 12 months as the clinical calendar resolves uncertainty and reduces tail-risk hedging demand. | →Stable |
| CounterElevated put buying in small-cap biotechs often reflects hedging by investors who are long the stock, not directional bets against the company. | ||
The company's entire value depends on zovegalisib (RLY-2608), creating extreme binary risk where a clinical setback could erase most of the current $3.3 billion market cap without any diversifying revenue stream. Bear case | Pipeline diversification emerges with a second late-stage asset entering clinical development within 12 months, reducing single-asset dependence. | →Stable |
| CounterFocused biotechs with a single compelling mechanism often generate superior returns by concentrating capital on the highest-probability asset rather than diluting it across a broad pipeline. | ||
Free cash flow is deeply negative at -1,135% of revenue, the Piotroski F-Score is a weak 2 out of 9, and there is no competitive moat, indicating the business fundamentals are far below the threshold required for confident position sizing. Quality breakdown | Cash burn rate narrows meaningfully as clinical milestones reduce operating expenses or partnership capital offsets losses over the next year. | →Stable |
| CounterPre-revenue biotechs universally score poorly on profitability metrics; the relevant measure is cash runway and clinical catalyst proximity, not current earnings quality. | ||
Analysts see 66% upside to their consensus price target, yet 18% of shares are sold short, reflecting a market-wide conviction that the bullish analyst thesis will not materialize in the near term. Key risks | Short interest falls below 12% over the next year as clinical data reduces uncertainty and short sellers cover positions. | →Stable |
| CounterHigh short interest can itself become a catalyst if positive clinical data forces a short squeeze, compressing the discount far faster than fundamental improvement alone. | ||
The put-to-call ratio stands at 4.40 with implied volatility near 185%, indicating the options market is pricing in a high probability of significant downside, consistent with binary clinical event risk rather than steady business execution.
→StableOptions
- Expectation
- Put-to-call ratio drops below 2.0 within 12 months as the clinical calendar resolves uncertainty and reduces tail-risk hedging demand.
CounterElevated put buying in small-cap biotechs often reflects hedging by investors who are long the stock, not directional bets against the company.
The company's entire value depends on zovegalisib (RLY-2608), creating extreme binary risk where a clinical setback could erase most of the current $3.3 billion market cap without any diversifying revenue stream.
→StableBear case
- Expectation
- Pipeline diversification emerges with a second late-stage asset entering clinical development within 12 months, reducing single-asset dependence.
CounterFocused biotechs with a single compelling mechanism often generate superior returns by concentrating capital on the highest-probability asset rather than diluting it across a broad pipeline.
Free cash flow is deeply negative at -1,135% of revenue, the Piotroski F-Score is a weak 2 out of 9, and there is no competitive moat, indicating the business fundamentals are far below the threshold required for confident position sizing.
→StableQuality breakdown
- Expectation
- Cash burn rate narrows meaningfully as clinical milestones reduce operating expenses or partnership capital offsets losses over the next year.
CounterPre-revenue biotechs universally score poorly on profitability metrics; the relevant measure is cash runway and clinical catalyst proximity, not current earnings quality.
Analysts see 66% upside to their consensus price target, yet 18% of shares are sold short, reflecting a market-wide conviction that the bullish analyst thesis will not materialize in the near term.
→StableKey risks
- Expectation
- Short interest falls below 12% over the next year as clinical data reduces uncertainty and short sellers cover positions.
CounterHigh short interest can itself become a catalyst if positive clinical data forces a short squeeze, compressing the discount far faster than fundamental improvement alone.
TrendMatrix Research · core thesis
Engine thesis — one sentence
Relay Therapeutics is a cash-burning clinical-stage biotech with a single lead asset (zovegalisib) that currently trades well below analyst price targets, but pipeline concentration and weak business fundamentals make this a speculative holding requiring clear clinical progress to justify the premium.
Falsifiable statement — pillar-level invalidators below. Engine-derived; not personalized advice.
Per-dimension breakdown
Quality
1.5/10data confidence 100%| Component | Sub-score |
|---|---|
| ROE | 0.0 |
| ROA | 0.0 |
| Gross margin | 0.0 |
| Net margin | 0.0 |
| Current ratio | 5.0 |
| FCF quality | 0.0 |
| Moat | 4.0 |
| Piotroski F | 3.3 |
- ▸Cash-burning: FCF -1135% of revenue
- ▸No competitive moat
- ▸Weak Piotroski F-Score: 3/9
- ▸Quality concerns
Growth
5.0/10data confidence 50%Momentum
7.5/10data confidence 100%| Component | Sub-score |
|---|---|
| RSI | 4.2 |
| MACD | 10.0 |
| OBV | 10.0 |
| MA position | 9.0 |
| Volume | 4.3 |
- ▸Overbought (RSI 76)
- ▸Volume accumulation (rising OBV)
- ▸Above 200-day MA
Sentiment
7.3/10data confidence 100%| Component | Sub-score |
|---|---|
| Analyst rating | 8.3 |
| Price target | 8.2 |
| erm sentiment | 4.7 |
- ▸Analyst upside: 26%
Insider
5.0/10data confidence 75%| Component | Sub-score |
|---|---|
| materiality | 3.0 |
| insider conviction | 2.0 |
| holder change | 10.0 |
- ▸Notable insider selling — $5,062,400 (0.123% of mkt cap)
- ▸Institutions accumulating
Peer rank
4.1/10data confidence 80%| Component | Sub-score |
|---|---|
| value rank | 5.0 |
| quality rank | 4.2 |
| growth rank | 1.5 |
Technical
3.9/10data confidence 100%| Component | Sub-score |
|---|---|
| bollinger | 1.4 |
| support resistance | 0.7 |
| 52w position | 9.5 |
Risk (lower is worse)
3.0/10data confidence 100%| Component | Sub-score |
|---|---|
| short interest | 1.5 |
| days to cover | 2.3 |
| volatility | 0.0 |
| put call | 2.7 |
| implied vol | 0.0 |
| beta | 4.4 |
| debt equity | 9.8 |
- ▸High short interest justified: 20%
- ▸Elevated put/call: 1.60
- ▸High IV: 108%
- ▸Concentration risks: 1 HIGH (10-K Item 1A — sized via position_sizing, validated via buy_confidence)
Catalyst
4.5/10data confidence 100%| Component | Sub-score |
|---|---|
| erm | 5.0 |
| earnings history | 3.3 |
| earnings timing | 5.0 |
| surprise avg | 4.6 |
- ▸Earnings concerns: 2B/2M
How the verdict was assembled
Engine trigger
Quality below minimum threshold.
Engine technical detail
verdict_path:
L1:HARD_BLOCKPassed (7)
- MOMENTUM:7.5>=5.5
- INSIDER:OK
- 8K:CLEAN
- NEWS_EVENTS:NONE_RECENT
- EARNINGS_PROXIMITY:30d clear
- SEMI_CYCLE_PEAK:CLEAR
- MATERIALS_CYCLE_PEAK:CLEAR
Failed (1)
- ASYMMETRY:0.6<1.5@spot
Warning (0)
none
Reward-to-Risk
0.63
Upside
+9.4%
Downside
15.0%
Sizing output
AVOID
Setup— — No clear chart pattern; technical signals are mixed
EdgeNo clear edge — No clear edge identified
SuitabilitySpeculative — Binary industry: Biotechnology
Investment implication
The L1 gate blocked the positive-verdict path: a hard-floor threshold was breached, so dimensional pillars — including Momentum at 7.5 could not lift the engine output above the verdict floor. Failed gate signal: ASYMMETRY:0.6<1.5@spot.
The strongest dimensions are Momentum at 7.5, Sentiment at 7.3, and Value at 6.0; the weakest are Quality at 1.5, Risk (lower is worse) at 3.0, and Technical at 3.9. The V9 engine flagged 1 failed gate, producing an asymmetric reward-to-risk of 0.63 and an engine sizing output of AVOID.
What would invalidate the thesis
Falsifying conditions — when triggered, the corresponding pillar's thesis is invalidated.
- P1Pipeline Concentration Single Asset
Trip ifPrice drops below $10, more than 33% below the current $14.96, on a clinical trial failure or clinical hold for zovegalisib.
- P2Quality Floor Failure Cash Burn
Trip ifCash and equivalents falls below 12 months of runway based on current quarterly burn rate exceeding $50 million per quarter.
- P3Analyst Upside Vs Short Interest
Trip ifShort interest rises above 25% of float or implied volatility exceeds 220%, signaling increased market disbelief in the bull case.
- P4Options Market Bearish Signal
Trip ifPut-to-call ratio remains above 3.5 for more than 60 consecutive days, indicating sustained options market bearishness ahead of key catalysts.